ALX Oncology Holdings Q3 EPS $(1.24) Misses $(0.87) Estimate
Portfolio Pulse from Benzinga Newsdesk
ALX Oncology Holdings (NASDAQ:ALXO) reported a Q3 EPS loss of $(1.24), missing the consensus estimate of $(0.87) by 42.53%. This represents a 74.65% increase in losses compared to $(0.71) per share in the same quarter last year.
November 13, 2023 | 10:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ALX Oncology Holdings reported a larger than expected quarterly loss, with EPS at $(1.24) versus the $(0.87) estimate, indicating a significant year-over-year increase in losses.
The reported EPS of $(1.24) is significantly below the analyst consensus estimate, which typically leads to negative investor sentiment and could result in a short-term decline in the stock price. The magnitude of the miss and the year-over-year deterioration in performance are likely to be viewed unfavorably by the market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100